[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648827":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":41,"collaborators":20,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":20,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":20,"enrollmentInfo":52,"targetDuration":20,"studyType":55,"phases":56,"briefSummary":59,"conditions":60,"keywords":20,"overallStatus":62,"whyStopped":20,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Tianjin Medical University Cancer Institute and Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Zeprumetostat + X","EXPERIMENTAL","Zeprumetostat+JAK1 inhibitor\u002FGemoX",[13],"Drug: Zeprumetostat( an EZH2 inhibitor) + X",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Zeprumetostat( an EZH2 inhibitor) + X","Zeprumetostat( an EZH2 inhibitor) + JAK1 inhibitor or GemOx",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Zhang huilai, MD","CONTACT","+86-18622221228","huilaizhangtz@163.com",[28],{"facility":29,"status":20,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":20},"Tianjin Cancer Hospital","Tianjin","Tianjin Municipality","300060","China","CN",{"type":36,"coordinates":37},"Point",[38,39],117.17667,39.14222,{"lat":39,"lon":38},{"type":42,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100648827","phase-1-multi-cohort-study-of-zeprumetostat-combinations-for-relapsedrefractory-ptcl-100648827",false,"NCT07724782","Multi-Cohort Study of Zeprumetostat Combinations for Relapsed\u002FRefractory PTCL","A Multi Cohort Exploratory Clinical Study of the EZH2 Inhibitor Zeprumetostat Combination Regimen in Relapsed\u002FRefractory Peripheral T Cell Lymphoma","Inclusion Criteria:\n\n1. Age 18 years or older, both males and females are eligible;\n2. Histologically confirmed peripheral T-cell lymphoma (PTCL) including PTCL-NOS and TFHL that has relapsed or is refractory after at least one line of systemic therapy. The definitions are as follows:\n\n   Relapse: Patients who achieved a Complete Response (CR) in previous treatments and have new lesions at the original site or elsewhere; Refractory: Patients who did not achieve CR after adequate treatment. For nasal-type NK\u002FT-cell lymphoma, previous treatments must have included a chemotherapy regimen containing asparaginase;\n3. Patients who have undergone prior hematopoietic stem cell transplantation are allowed;\n4. ECOG PS 0-2\n5. Life expectancy greater than 3 months.\n6. Adequate organ function\n7. Contraception during study\n8. Informed consented\n\nExclusion Criteria:\n\n1. Prior treatment with EZH2 inhibitors or EZH1\u002F2 inhibitors before enrollment;\n2. Peripheral T-cell lymphoma of subtypes other than PTCL-NOS and TFHL;\n3. History of other primary invasive malignancies that have not been in remission or have been in remission for no more than 3 years;\n4. Central nervous system involvement (meningeal or parenchymal);\n5. Known hypersensitivity to any study drugs;\n6. Participation in another clinical trial of an investigational drug within 4 weeks prior to the start of the study.\n7. Pregnant or lactation\n8. Active infection.\n9. Diseases and medical history:\n\n   1. Requires continuous treatment with strong or moderate CYP3A inhibitors or CYP3A inducers\n   2. Has multiple factors affecting oral medication administration (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, etc.);\n   3. Has a history of psychoactive substance abuse that cannot be discontinued\n   4. Has any severe and\u002For uncontrolled disease.\n10. Uncontrollable autoimmune disease,\n11. Not able to comply to the protocol for mental or other unknown reasons\n12. Any other condition that, in the investigator's judgment, makes the patient unsuitable for study participation.","ALL","18 Years",{"count":53,"type":54},33,"ESTIMATED","INTERVENTIONAL",[57,58],"PHASE1","PHASE2","This is a single-arm, multi-cohort, multicenter, phase Ib\u002FIIa clinical study designed to evaluate the safety and efficacy of Zeprumetostat (an EZH2 inhibitor) in combination with different therapeutic agents\u002Fregimens - specifically, the JAK1 inhibitor golidocitinib and the GemOx chemotherapy regimen (gemcitabine plus oxaliplatin) - in patients with relapsed or refractory peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) and T-follicular helper cell lymphoma (TFHL). The trial comprises a phase Ib dose-escalation phase and a phase IIa dose-expansion phase. Two combination cohorts are established: Cohort A (zemitostatin + golidocitinib) and Cohort B (zemitostatin + GemOx). Subjects will be randomly assigned to either Cohort A or Cohort B.",[61],"PTCL-NOS","NOT_YET_RECRUITING","2026-07-21",{"date":65,"type":66},"2026-07-24","ACTUAL",{"date":68,"type":54},"2026-08-01",{"date":70,"type":54},"2031-07-30",{"name":5,"class":6},1]